MedTrace Logo

Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment

NCT04298242 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-11-22

No results posted yet for this study

Summary

The primary purpose of this protocol is to assess the ExAblate 2100 MR guided high intensity focused ultrasound device as an intervention for treatment of advanced stage pancreatic adenocarcinoma.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DEVICE

ExAblate 2100

A non-invasive thermal ablation device fully integrated with an MR imaging system

Sponsors & Collaborators

Principal Investigators

  • Pejman Ghanouni · Stanford University

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-22
Primary Completion
2021-06-15
Completion
2021-06-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298242 on ClinicalTrials.gov